The Oncology Institute, Inc. (TOI)
- Previous Close
0.5500 - Open
0.5070 - Bid 0.5100 x 100
- Ask 0.5315 x 100
- Day's Range
0.4504 - 0.5500 - 52 Week Range
0.3300 - 2.6550 - Volume
673,686 - Avg. Volume
170,124 - Market Cap (intraday)
39.08M - Beta (5Y Monthly) 0.83
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8100 - Earnings Date Aug 6, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.00
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
theoncologyinstitute.com800
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: TOI
Performance Overview: TOI
Trailing total returns as of 5/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TOI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TOI
Valuation Measures
Market Cap
39.08M
Enterprise Value
93.08M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.11
Price/Book (mrq)
0.95
Enterprise Value/Revenue
0.27
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-21.29%
Return on Assets (ttm)
-17.68%
Return on Equity (ttm)
-104.45%
Revenue (ttm)
342.71M
Net Income Avi to Common (ttm)
-59.66M
Diluted EPS (ttm)
-0.8100
Balance Sheet and Cash Flow
Total Cash (mrq)
65.83M
Total Debt/Equity (mrq)
290.18%
Levered Free Cash Flow (ttm)
-14.58M